Clotilde Allavena

Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

François-Xavier Lescure, Hitoshi Honda, Robert Fowler et al. · The Lancet Respiratory Medicine · 2021 · 248 citations · Full text

Medicine, Immunology, Pharmacotherapy +17

The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies

Jérémy Manry, Paul Bastard, Adrian Gervais et al. · Proceedings of the National Academy of Sciences · 2022 · 193 citations · Full text

Life Sciences, Immunology, Infectious Diseases +15

Opportunistic infections occurring during highly active antiretroviral treatment

C. Michelet, C. Arvieux, Cécile François et al. · AIDS · 1998 · 184 citations

Life Sciences, Infectious Diseases, Microbiology +17

Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor

Sophie Grabar, Christian Pradier, Emmanuelle Le Corfec et al. · AIDS · 2000 · 177 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

François Raffi, Abdel G. Babiker, Laura Richert et al. · The Lancet · 2014 · 176 citations

Pharmacy, Infectious Diseases, Pharmacology +13